Tetraphase ditches series B round for larger $45 million series C
This article was originally published in Scrip
Executive Summary
Tetraphase Pharmaceuticals has abandoned the second tranche of a series B financing round in favour of raising $45 million in a series C round led by Excel Venture Management.